BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol 2014; 6(10): 738-744 [PMID: 25349644 DOI: 10.4254/wjh.v6.i10.738]
URL: https://www.wjgnet.com/2150-5349/full/v6/i10/738.htm
Number Citing Articles
1
Konstantinos Tziomalos, Vasilios G. Athyros, Paschalis Paschos, Asterios Karagiannis. Nonalcoholic fatty liver disease and statinsMetabolism 2015; 64(10): 1215 doi: 10.1016/j.metabol.2015.07.003
2
Timothy M.E. Davis, Kirsten E. Peters, S. A. Paul Chubb, Leon A. Adams, Gary P. Jeffrey, Wendy A. Davis. Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes StudyJournal of Clinical Medicine 2020; 9(11): 3409 doi: 10.3390/jcm9113409
3
Stephen A. Harrison, Mark M. Pence, Amy N. Stratton, Dawn M. Torres. Zakim and Boyer's Hepatology2018; : 406 doi: 10.1016/B978-0-323-37591-7.00027-6
4
Hua Cao, Zhi-Xiang Chen, Kai Wang, Meng-Meng Ning, Qing-An Zou, Ying Feng, Yang-Liang Ye, Ying Leng, Jian-Hua Shen. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effectScientific Reports 2016; 6(1) doi: 10.1038/srep28676
5
Rachana S. Bhimanwar, Amit Mittal, Snehal Chaudhari, Vikas Sharma. Recent advancements in the structural exploration of TGR5 agonists for diabetes treatmentRSC Medicinal Chemistry 2024; 15(9): 3026 doi: 10.1039/D4MD00473F
6
Carla Sá, Ana Rita Oliveira, Cátia Machado, Marisa Azevedo, Cristina Pereira-Wilson. Effects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucosideEvidence-Based Complementary and Alternative Medicine 2015; 2015: 1 doi: 10.1155/2015/647832
7
Aybike Birerdinc, Zobair Younossi. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?Journal of Hepatology 2015; 62(4): 761 doi: 10.1016/j.jhep.2015.01.005
8
Haiyan Zhou, Maeda Toshiyoshi,, Wenli Zhao, Ye Zhao, Yan Zhao. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTsMedicine 2023; 102(26): e33981 doi: 10.1097/MD.0000000000033981
9
Yajun Duan, Ke Gong, Suowen Xu, Feng Zhang, Xianshe Meng, Jihong Han. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeuticsSignal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01125-5
10
Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trialTherapeutic Advances in Gastroenterology 2016; 9(2): 152 doi: 10.1177/1756283X15621232
11
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An updateMetabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
12
Ju Youn Kim, Feng He, Michael Karin. From Liver Fat to Cancer: Perils of the Western DietCancers 2021; 13(5): 1095 doi: 10.3390/cancers13051095
13
Adnan Hussain Gora, Saima Rehman, Viswanath Kiron, Jorge Dias, Jorge M. O. Fernandes, Pål Asgeir Olsvik, Prabhugouda Siriyappagouder, Ioannis Vatsos, Ulrike Schmid-Staiger, Konstantin Frick, Miguel Cardoso. Management of Hypercholesterolemia Through Dietary ß-glucans–Insights From a Zebrafish ModelFrontiers in Nutrition 2022; 8 doi: 10.3389/fnut.2021.797452
14
Graciela Arguello, Elisa Balboa, Marco Arrese, Silvana Zanlungo. Recent insights on the role of cholesterol in non-alcoholic fatty liver diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015; 1852(9): 1765 doi: 10.1016/j.bbadis.2015.05.015